Jan Marsal

Sweden

Research Interests

Explore related searches

Professors in Sweden Professors in Immunology Immunology professors in Sweden

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (12)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

LINKED CONTENT This article is linked to Bergqvist et al papers. To view these articles, visit https://doi.org/10.1111/apt.16927 and https://doi.org/10.1111/apt.17112

Year:

2022

Year:

2022

Year:

2022

Collaborators (5)

Jonas Halfvarson

Örebro universitet Institutionen för medicinska vetenskaper

SWEDEN

View details

Mohammad Kadivar

Assistant Professor

Technical University of Denmark

DENMARK

View details

Martin Neovius

Karolinska University Hospital

SWEDEN

View details

Sven Almer

Karolinska Institutet

SWEDEN

View details

Jordan Axelrad

Assistant Professor

NYU Langone Health

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jan Marsal

Research Interests

Explore related searches

Contact this professor

Articles (12)

Inflammatory Bowel Disease, Periconceptional Disease Activity, and Risk of Major Congenital Anomalies: A Nationwide Cohort Study

Endoscopic scoring of immune-mediated colitis disease activity

Histologic Remission in Inflammatory Bowel Disease and Female Fertility: A Nationwide Study

Hyaluronic Acid-Conjugated Thermoresponsive Polymer-Based Bioformulation Enhanced Wound Healing and Gut Barrier Repair of a TNBS-Induced Colitis Injury Ex Vivo Model in a Dynamic Perfusion Device

Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease

Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study

Alkaline sphingomyelinase (NPP7) impacts the homeostasis of intestinal T lymphocyte populations

Emergency subtotal colectomy rates in relation to anti-TNF therapy in inflammatory bowel disease patients: comparison of retrospective cohorts

New solutions for an old problem: Current developments in oral contrast agents,Neue Lösung für ein altes Problem: Aktuelle Entwicklungen bei oralen Kontrastmitteln

Letter: to switch or not to switch, that is the question—author's reply

Editorial: intravenous to subcutaneous vedolizumab—switch without glitch! Authors' reply

Real‐world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease

Collaborators (5)

Jonas Halfvarson

Mohammad Kadivar

Martin Neovius

Sven Almer

Jordan Axelrad

Make your next move.